Cantor Fitzgerald Reiterates Buy Rating, $6 PT for Sunesis Pharmaceuticals

In a report published earlier today, Cantor Fitzgerald L.P. reiterated its Buy rating and $6.00 price target for Sunesis Pharmaceuticals, Inc.

. Cantor Fitzgerald went on to say “Sunesis has reported that the planned interim safety checkpoint from its Phase III VALOR trial for AML has occurred and an independent data and safety monitory board (DSMB) has recommended that the trial continue without adjustment. This planned safety analysis is in addition to the interim look likely to take place in 3Q:12, which will examine safety as well as efficacy, with potential for stop early for efficacy or futility or sample size adjust with an additional 225 patients.” Sunesis Pharmaceuticals, Inc. closed yesterday at $2.71.